Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diabetes & aspirin

This article was originally published in The Tan Sheet

Executive Summary

Nearly half of American adults with diabetes are not using aspirin therapy to reduce their risk of recurrent heart attack or stroke, nor have they discussed such therapy with their physician, according to a survey released Nov. 21 by the American College of Preventive Medicine. Results were drawn from an eight-day online survey of 1,299 consumers over the age of 40 that was conducted in October 2004. The survey was conducted by Harris Interactive and was supported by an unrestricted educational grant from Bayer Healthcare. Approximately 15% of the respondents indicated they have diabetes, which places them at higher risk of cardiovascular-related events, according to the American Diabetes Association. While nearly half of the group with diabetes considered themselves "extremely knowledgeable" about aspirin, only 25% agreed that "the benefits of aspirin therapy strongly outweigh the risks"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel